Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease
1 other identifier
interventional
53
1 country
9
Brief Summary
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2 prostate-cancer
Started Dec 2004
Shorter than P25 for phase_2 prostate-cancer
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2005
CompletedFirst Submitted
Initial submission to the registry
February 23, 2005
CompletedFirst Posted
Study publicly available on registry
February 24, 2005
CompletedSeptember 17, 2008
September 1, 2008
February 23, 2005
September 16, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
prostate cancer
prostate-specific antigen (PSA) response
Interventions
Eligibility Criteria
You may qualify if:
- At least 18 years of age.
- Metastatic disease.
- One previous treatment including docetaxel (Taxotere).
- At least 3 weeks since last surgery/radiation/chemotherapy
- ECOG Performance Status of 0, 1 or 2
You may not qualify if:
- Active brain metastases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (9)
Kaiser Permanente Medical Center
Vallejo, California, 94589, United States
Georgia Cancer Specialists
Tucker, Georgia, 30084, United States
University of Maryland Medical System
Baltimore, Maryland, 21201, United States
Washington University School of Medicine
St Louis, Missouri, 63310, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Kaiser Permanente NW Oncology Clinic
Portland, Oregon, 97227, United States
Oregon Health & Science University
Portland, Oregon, 97239, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
University of Washington
Seattle, Washington, 98109, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
February 23, 2005
First Posted
February 24, 2005
Study Start
December 1, 2004
Study Completion
February 1, 2005
Last Updated
September 17, 2008
Record last verified: 2008-09